Stockhub

Spexis AG: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

27 September 2022

  • curprev 23:4823:48, 27 September 2022 87.224.91.72 talk 956 bytes +956 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase 1 development stage to treat..."
Retrieved from "https://stockhub.co/research/Spexis_AG"